Company Filing History:

13 out of 469

Brown University

patents

2 out of 32

Cytotherapeutics, Inc.

where one patent can have more than one assignee

Years Active: 1996-2007

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7198785 - Systems and methods related to degradation of uremic toxins (2007-04-03),

2. 6960351 - Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products (2005-11-01),

3. 6322804 - Implantable biocompatible immunoisolatory vehicle for the delivery of selected therapeutic products (2001-11-27),

4. 6083523 - Implantable biocompatable immunoisolatory vehicle for delivery of (2000-07-04),

5. 5874099 - Methods for making immunoisolatary implantable vehicles with a (1999-02-23),

6. 5871767 - Methods for treatment or prevention of neurodegenerative conditions (1999-02-16),

7. 5869077 - Methods for treating diabetes by delivering insulin from biocompatible (1999-02-09),

8. 5837234 - Bioartificial organ containing cells encapsulated in a permselective (1998-11-17),

9. 5834001 - Methods for making immunoisolatory implantable vehicles with a (1998-11-10),

10. 5800829 - Methods for coextruding immunoisolatory implantable vehicles with a (1998-09-01),

11. 5800828 - Implantable biocompatible immunoisolatory vehicle for delivery of (1998-09-01),

12. 5798113 - Implantable biocompatible immunoisolatory vehicle for delivery of (1998-08-25),

13. 5656372 - Apparatus for forming hollow fibers and said fibers (1997-08-12),

14. 5550050 - Method for implanting encapsulated cells in a host (1996-08-27),

15. 5480598 - Process of and apparatus for making hollow fibers (1996-01-02),

Title: Michael J Lysaght: Innovator in Uremic Toxin Treatment and Biocompatible Delivery Systems.

Introduction

Michael J Lysaght is a prominent inventor based in Greenwich, Rhode Island, known for his significant contributions to the field of medical innovations. With a total of 15 patents to his name, he has focused on developing advanced systems and methods for treating uremic toxins and creating biocompatible delivery vehicles for therapeutic products.

Latest Patents

One of Lysaght's latest patents involves systems and methods related to the degradation of uremic toxins. This invention addresses the treatment of uremic toxins in vivo using enzymes or cells that can produce these enzymes. The treatment is particularly beneficial for individuals suffering from renal disease, gout, or those undergoing chemotherapy. The oral delivery composition aims to reduce blood concentrations of non-protein nitrogen compounds by delivering uremic toxin-treating enzymes, such as urease and uricase, to the intestines. Another notable patent is for an implantable biocompatible immunoisolatory vehicle designed for the delivery of therapeutic products. This vehicle allows for the implantation of cells that produce necessary products while protecting them from the immune system, making it suitable for delivering insulin and other high molecular weight products.

Career Highlights

Throughout his career, Michael J Lysaght has worked with esteemed institutions such as Brown University and Cytotherapeutics, Inc. His work has significantly impacted the medical field, particularly in the treatment of chronic conditions related to uremic toxins.

Collaborations

Lysaght has collaborated with notable professionals in his field, including Frank T Gentile and Keith E Dionne. These collaborations have contributed to the advancement of his innovative projects and patents.

Conclusion

Michael J Lysaght's work exemplifies the spirit of innovation in medical technology, particularly in the treatment of uremic toxins and the development of biocompatible delivery systems. His contributions continue to pave the way for advancements in healthcare solutions.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com